Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;2(3):100097.
doi: 10.1016/j.jcvp.2022.100097. Epub 2022 Jun 28.

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases

Daniele Focosi  1 , Federica Novazzi  2   3 , Andreina Baj  2   3 , Francesca Drago Ferrante  2 , Sara Boutahar  2   3 , Angelo Paolo Genoni  2   3 , Daniela Dalla Gasperina  4   3 , Fabrizio Maggi  2   3
Affiliations

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases

Daniele Focosi et al. J Clin Virol Plus. 2022 Aug.
No abstract available

Keywords: Omicron; SARS-CoV-2; Sotrovimab; Spike: E340.

PubMed Disclaimer

Conflict of interest statement

We declare we have no conflict of interest related to this manuscript.

References

    1. Focosi D., Maggi F., Franchini M., McConnell S., Casadevall A. Analysis of immune escape variants from antibody-based therapeutics against COVID-19: a systematic review. Int. J. Mol. Sci. 2022;23:29. - PMC - PubMed
    1. Therapeutic Goods Administration. Australian Product Information – XEVUDY (Sotrovimab) concentrated Injection solution for infusion. (2021). Accessed on December 22, 2021 at https://www.tga.gov.au/sites/default/files/xevudy-pi.pdf.
    1. Gupta A., Gonzalez-Rojas Y., Juarez E., Crespo Casal M., Moya J., Rodrigues Falci D., et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022 - PMC - PubMed
    1. Rockett R.J., Basile K., Maddocks S., Fong W., Agius J.E., Johnson-Mackinnon J., et al. Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use. N. Engl. J. Med. 2021 - PMC - PubMed
    1. Huygens S., Oude Munnink B., Gharbharan A., Koopmans M., Rijnders B. High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant. 2022:2022.04.06.22273503. - PMC - PubMed